Brief: Hutchmed Announces Positive Topline Phase III Trial Of Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia
07/01/2026 24:02
Jan 6 (Reuters) - HUTCHMED (China) Ltd 0013.HK: HUTCHMED ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE III PART OF ESLIM-02 TRIAL OF SOVLEPLENIB FOR WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA IN CHINA HUTCHMED (CHINA) LTD - PHASE III TRIAL OF SOVLEPLENIB MEETS PRIMARY ENDPOINT Source text: ID:nGNX40BshT Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation